Waters' BD Deal Hits Its Stride: Pricing, New Products, and a Raised Guide
Organic growth accelerates to 9% cc, BD businesses inflect to mid-single digits, and management lifts full-year EPS guidance.
WAT · Earnings Call · 2026-08-04
The Pivot After the Close
Waters Corporation enters its second quarter under the enlarged footprint with a striking acceleration. The stock is up 28% over the last 90 days, and the company's own full-year organic guidance was raised. The narrative is no longer about digestion of the BD Biosciences and Diagnostic Solutions acquisition—it's about rapid-fire execution and compounding day plan initiatives. As CEO Udit Batra said on the call, "We built outstanding momentum in our newly acquired businesses in their first full quarter under Waters' leadership, driving an acceleration to mid-single-digit growth as the controlled actions from a 180-day plan have quickly taken hold." “We built outstanding momentum in our newly acquired businesses in their first full quarter under Waters' leadership, driving an acceleration to mid-single-digit growth as the controlled actions from a 180-day plan have quickly taken hold.” — Udit Batra, President and Chief Executive Officer · 2026-08-04 That plan is now surfacing in the numbers: the acquired businesses grew 4% as reported, a 400-basis-point improvement versus the prior quarter's flat full-quarter rate. The turnaround is not just about market recovery. Management has installed a pricing discipline (a deal desk, escalation protocols, and list price increases) that lifted net price realization to 90 basis points in Q2, versus the 50 basis points historically embedded. As CFO Amol Chaubal noted, "So Q2, Evie, we did 0.9% versus the traditional 0.5%." “So Q2, Evie, we did 0.9% versus the traditional 0.5%.” — Amol Chaubal, Senior Vice President and Chief Financial Officer · 2026-08-04 This is an early step toward the 150-basis-point target, and it is already fueling the mid-single-digit exit-rate narrative.New Product Engines: BACTEC FXI and FACSDiscover A7
The most tangible proof that Waters is not just mining an old installed base is the new product cadence. The BACTEC FXI blood culture system, cleared by the FDA in May, is already launching in Japan and Europe and is now commercially available in the U.S. Udit Batra framed it as a direct analogue to the Alliance iS replacement play: "It's a replacement business regardless. That's the similarity. It's 12,000 instruments that are ripe for replacement, 4,500 in the U.S. alone. Excellent uptake of FXI." “It's a replacement business regardless. That's the similarity. It's 12,000 instruments that are ripe for replacement, 4,500 in the U.S. alone. Excellent uptake of FXI.” — Udit Batra, President and Chief Executive Officer · 2026-08-04 The reagent-rental model adds a second revenue layer, and the compliance review of ~700 U.S. contracts is a line item that could drive further upside. Meanwhile, the FACSDiscover A7—an instrument designed to close a key gap in the flow cytometry portfolio—launches on September 15. The company sees it as a vehicle to recapture share in a market that has been a drag, especially in China, and to ride the improving U.S. biotech and academic funding environment. The product pipeline is also feeding growth in legacy Analytical Sciences: the company launched two new high-resolution mass specs and bioseparations products designed specifically for GLP-1 peptide analysis. Indeed, GLP-1 testing grew over 40% in the quarter, and management noted it is running well ahead of the 30 basis points assumed in the idiosyncratic growth-driver pool. “GLP-1 testing part of the business grew over 40% this quarter. Broad-based growth across virtually every geography.” — Udit Batra, President and Chief Executive Officer · 2026-08-04Financial Trajectory and Guide
The financial picture is one of accelerating top-line growth coupled with disciplined cost action. Management raised full-year organic constant-currency guidance to 7–9% and held the adjusted EBIT margin at 28.2% despite a stronger dollar—absorbing the FX headwind with $75 million of incremental cost savings. Guidance for adjusted EPS was raised to $14.45–$14.65, representing 12–14% constant-currency growth. The Q3 guide of $3.95–$4.05 (16–19% growth) reflects the phasing of cost benefits and new product launches. Cost actions are delivering ahead of schedule. The $200 million run-rate savings target is already 4% of the cost base, compared to the 7.5% benchmark from prior integrates, leaving room for further network consolidation. As Udit Batra said, "We have a fair number of initiatives that we want to continue to implement beyond the $200 million that we've already delivered." “We have a fair number of initiatives that we want to continue to implement beyond the $200 million that we've already delivered.” — Udit Batra, President and Chief Executive Officer · 2026-08-04 This is echoed in the prior-quarter call where he had flagged the 180-day plan as "having quite an early impact." “having quite an early impact” — Udit Batra, President and Chief Executive Officer · 2026-05-05 and in February when he described the deal-desk model as "take away the ability for regions and sales teams to discount." “take away the ability for regions and sales teams to discount” — Udit Batra, President and Chief Executive Officer · 2026-02-09 The shift is visible in the fundamentals, where operating income has swung negative on a GAAP basis due to acquisition-related charges. Operating income was -$88M in the latest reported quarter—but the adjusted EPS of $3.05 and free cash flow of $202M show the underlying profitability engine remains intact.Riding the Global Wave
Waters is also benefiting from industry tailwinds. The pharma reshoring theme is increasingly tangible, with 76 tracked U.S. expansion sites and ~$100B of CapEx funneling into instrument outfitting. Management estimates that 70% of those sites are accounts where Waters already holds high share. The company is also leveraged to the global recovery in academic and government funding, which returned to double-digit growth this quarter. The order backdrop is strong, and with the instrument replacement cycle still "in the middle innings," the runway into 2027 looks well-supported.The story is not without its puts and takes—China Flow Research remains a drag, and the FX headwind is real—but the broad-based acceleration, the new product cadence, and the disciplined execution make this a name in motion. The market's +28% move over the last 90 days appears to be pricing in the inflection, and the company's raised guidance provides a clear signal that management believes the momentum is durable.Waters is better positioned today than at any point in recent history with a broad portfolio, a larger installed base and the cleanest set of growth catalysts we've ever had.